Scinai Immunotherapeutics Ltd. (SCNI) 10-Year Financial Performance & Capital Metrics

SCNI •

HealthcareBiotechnologyVaccines and Infectious Disease

AboutScinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.Show more

Revenue $658K
EBITDA -$7M +24.0%
Net Income $5M +173.8%
EPS (Diluted) 6.00 +135.7%
Gross Margin -88.15%
EBITDA Margin -1062.16%
Operating Margin -1312.77%
Net Margin 728.88%
ROE 177.37%
ROIC -61.06% +29.4%
Debt/Equity 0.21
Interest Coverage -6.00 +99.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 177.4%
✓Healthy 5Y average net margin of 728.9%
✓Trading at only 0.1x book value

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM303.87%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM224.43%

EPS CAGR

10Y-

5Y-

3Y-

TTM-100%

ROCE

10Y Avg-51.96%

5Y Avg-42.76%

3Y Avg-50.65%

Latest-63.2%

Peer Comparison

Vaccines and Infectious Disease

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
NVAXNovavax, Inc.	1.67B	10.14	3.93	64.69%	39.19%
SCNIScinai Immunotherapeutics Ltd.	3.03B	0.89	0.15		401.83%	58.65%		0.21
TNXPTonix Pharmaceuticals Holding Corp.	142.05M	13.97	-0.08	29.94%	-9.63%	-42.93%		0.04
INOInovio Pharmaceuticals, Inc.	65.34M	1.81	-0.46	-73.83%	-592.82%	-115.42%		0.17
IVVDInvivyd, Inc.	362.35M	1.69	-1.18		-119.63%	-64.32%		0.02
SPROSpero Therapeutics, Inc.	122.2M	2.17	-1.71	-53.77%	-122.56%	-165.46%		0.09
AVIRAtea Pharmaceuticals, Inc.	365.63M	4.68	-2.34			-46.56%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	658K
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	123.55K	72.32K	461.69K	708.92K	747.65K	559.8K	512.67K	1.24M
COGS % of Revenue	-	-	-	-	-	-	-	-	-	188.15%
Gross Profit+	0	0	0	0	0	-708.92K	-747.65K	-559.8K	-512.67K	-580K
Gross Margin %	-	-	-	-	-	-	-	-	-	-88.15%
Gross Profit Growth %	-	-	-	-	-	-	-5.46%	25.13%	8.42%	-13.13%
Operating Expenses+	2.9M	3.09M	6.8M	20.61M	22.69M	-2.28M	10.86M	11.06M	9.71M	8.06M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	1224.62%
Selling, General & Admin	871.81K	1.07M	1.4M	1.38M	2.81M	5.02M	7.63M	5.3M	4.5M	2.53M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	383.89%
Research & Development	1.91M	2.44M	5.58M	19.27M	19.88M	16.01M	3.25M	5.76M	5.21M	5.53M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	840.73%
Other Operating Expenses	-726K	-416K	-186K	-38.24K	0	-23.31M	-12K	0	-9K	0
Operating Income+	-2.9M	-3.09M	-6.8M	-20.61M	-22.69M	2.28M	-10.87M	-11.06M	-9.71M	-8.64M
Operating Margin %	-	-	-	-	-	-	-	-	-	-1312.77%
Operating Income Growth %	-38.83%	-6.48%	-120.07%	-203.15%	-10.1%	110.06%	-576.51%	-1.72%	12.25%	11%
EBITDA+	-2.74M	-2.93M	-6.67M	-20.54M	-22.23M	2.75M	-10.4M	-10.5M	-9.19M	-6.99M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-1062.16%
EBITDA Growth %	-42.98%	-6.84%	-128.05%	-207.68%	-8.24%	112.37%	-478.21%	-0.92%	12.45%	23.97%
D&A (Non-Cash Add-back)	161.62K	162.32K	123.55K	72.32K	461.69K	468.56K	471K	562K	514K	1.65M
EBIT	-2.9M	-3.09M	-6.8M	-20.61M	-22.69M	2.28M	-10.86M	-11.06M	-9.71M	-8.64M
Net Interest Income+	2.82K	14.28K	5.17K	-2.43M	-4.27M	-348K	-3.36M	3.05M	115K	-1.34M
Interest Income	2.83K	14.38K	5.04K	1.35M	8.3K	582	929	8.1M	122.68K	100.47K
Interest Expense	8	100	20.45K	3.78M	4.28M	348.93K	3.36M	5.05M	7.98K	1.44M
Other Income/Expense	283.33K	704.94K	-3.13M	-2.85M	-8.93M	-3.67M	2.67M	5.26M	3.21M	13.43M
Pretax Income+	-2.62M	-2.38M	-9.93M	-23.46M	-31.62M	-1.39M	-8.21M	-5.8M	-6.5M	4.8M
Pretax Margin %	-	-	-	-	-	-	-	-	-	728.88%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Net Income+	-2.62M	-2.38M	-9.93M	-23.46M	-31.62M	-1.39M	-8.21M	-5.8M	-6.5M	4.8M
Net Margin %	-	-	-	-	-	-	-	-	-	728.88%
Net Income Growth %	-31.33%	8.9%	-316.53%	-136.24%	-34.79%	95.62%	-492.06%	29.37%	-12.15%	173.78%
Net Income (Continuing)	-2.62M	-2.38M	-9.93M	-23.46M	-31.62M	-1.39M	-8.21M	-5.8M	-6.5M	4.8M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-396880.00	-282320.00	-790280.00	-999999.00	-999999.00	-12.40	-80.00	-30.80	-16.80	6.00
EPS Growth %	32.42%	28.87%	-179.92%	-81.68%	-7.87%	100%	-545.16%	61.5%	45.45%	135.71%
EPS (Basic)	-396880.00	-282320.00	-790280.00	-999999.00	-999999.00	-12.40	-87.60	-30.80	-16.80	6.00
Diluted Shares Outstanding	26.38K	33.77K	50.26K	65.36K	81.66K	110.81K	141.14K	188.52K	390.66K	806.37K
Basic Shares Outstanding	26.38K	33.77K	50.26K	65.35K	81.66K	110.81K	102.57K	188.52K	390.66K	806.37K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	9.48M	6.78M	21.64M	20.55M	21.17M	3.31M	17.84M	14.37M	5.45M	2.39M
Cash & Short-Term Investments	9.11M	6.57M	20.51M	20.29M	20.98M	2.93M	17.37M	14.07M	4.87M	1.96M
Cash Only	8.59M	4.08M	20.51M	20.29M	20.98M	2.93M	17.37M	14.07M	4.87M	1.96M
Short-Term Investments	517.39K	2.5M	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	71.22K	325.15K	0	330K	217K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	120.37
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	360.07K	198.3K	911.89K	102.42K	101.06K	33	-84.15K	250K	176K	131K
Total Non-Current Assets+	1.12M	1.03M	1.84M	7.75M	12.34M	14.4M	14.19M	12.7M	12.03M	11.06M
Property, Plant & Equipment	524.57K	374.53K	1.58M	7.55M	12.19M	14.25M	14.19M	12.7M	12.03M	11.06M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	0.06x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	525.6K	532.08K	0	0	0	147.31K	0	0	0	0
Other Non-Current Assets	73.66K	124.07K	252.9K	197.88K	150.16K	-150	0	0	0	0
Total Assets+	10.6M	7.82M	23.48M	28.3M	33.52M	17.71M	32.04M	27.07M	17.47M	13.45M
Asset Turnover	-	-	-	-	-	-	-	-	-	0.05x
Asset Growth %	123.73%	-26.28%	200.42%	20.54%	18.43%	-47.17%	80.93%	-15.51%	-35.45%	-23.03%
Total Current Liabilities+	436.03K	356.88K	1.98M	5.83M	5.49M	19.97M	2.44M	2.34M	1.78M	1.81M
Accounts Payable	238.93K	178.05K	1.79M	5.54M	4.94M	581.19K	999K	716K	535K	376K
Days Payables Outstanding	-	-	5.28K	27.97K	3.91K	299.24	487.71	466.84	380.89	110.86
Short-Term Debt	0	0	0	0	0	18.8M	248.36K	0	396K	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	225K
Other Current Liabilities	0	-190	0	0	0	0	-248.36K	0	-396K	0
Current Ratio	21.74x	19.01x	10.94x	3.53x	3.86x	0.17x	7.30x	6.15x	3.06x	1.32x
Quick Ratio	21.74x	19.01x	10.94x	3.53x	3.86x	0.17x	7.30x	6.15x	3.06x	1.32x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.56M	809.54K	5.33M	30.82M	46.87M	2.28M	28.61M	26.49M	20.26M	1.67M
Long-Term Debt	0	0	0	25.23M	35.84M	0	27.16M	20.08M	19.37M	260K
Capital Lease Obligations	0	0	0	0	1.97M	1.89M	1.45M	1.08M	797K	1.4M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.56M	809.54K	5.33M	5.59M	9.06M	382.69K	30.52K	5.33M	96K	3K
Total Liabilities	1.99M	1.17M	7.31M	36.65M	52.36M	22.25M	31.05M	28.83M	22.04M	3.47M
Total Debt+	0	0	0	25.23M	38.02M	20.9M	29.23M	21.54M	20.56M	2.09M
Net Debt	-8.59M	-4.08M	-20.51M	4.94M	17.03M	17.97M	11.86M	7.47M	15.69M	122K
Debt / Equity	-	-	-	-	-	-	29.77x	-	-	0.21x
Debt / EBITDA	-	-	-	-	-	7.60x	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	6.53x	-	-	-	-
Interest Coverage	-371746.74x	-30890.00x	-332.39x	-5.45x	-5.30x	6.54x	-3.23x	-2.19x	-1216.44x	-6.00x
Total Equity+	8.61M	6.65M	16.17M	-8.35M	-18.84M	-4.54M	982K	-1.76M	-4.57M	9.98M
Equity Growth %	102.23%	-22.77%	143.15%	-151.63%	-125.68%	75.89%	121.62%	-279.23%	-159.6%	318.36%
Book Value per Share	326.33	196.86	321.66	-127.72	-230.68	-40.98	6.96	-9.34	-11.70	12.37
Total Shareholders' Equity	8.61M	6.65M	16.17M	-8.35M	-18.84M	-4.54M	982K	-1.76M	-4.57M	9.98M
Common Stock	0	0	0	0	0	0	0	0	0	0
Retained Earnings	-20.45M	-23.07M	-35.47M	-56.46M	-92.76M	-101.05M	-110.04M	-115.83M	-122.33M	-117.54M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	653.92K	374.01K	0	0	0	0	-2.06M	-2.01M	-1.74M	-1.74M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.63M	-2.51M	-2.89M	-15.29M	-22.31M	-22.57M	-7.43M	-7.26M	-9.38M	-6.33M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-962.77%
Operating CF Growth %	-35.58%	4.91%	-15.28%	-429.52%	-45.9%	-1.14%	67.1%	2.17%	-29.14%	32.48%
Net Income	-2.62M	-2.38M	-9.93M	-23.46M	-31.62M	-1.3M	-8.21M	-5.8M	-6.5M	4.8M
Depreciation & Amortization	161.17K	162.32K	126.45K	69.53K	476.36K	757.91K	471K	562K	514K	1.65M
Stock-Based Compensation	191.2K	327.29K	149.16K	69.53K	1.07M	2.95M	2.76M	1.6M	1.14M	682K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-176.31K	-756.95K	7.67M	7.12M	7.64M	-25.17M	-3.15M	-4.08M	-3.89M	-13.57M
Working Capital Changes	-193.51K	145.61K	-901.54K	902.23K	126.26K	196.01K	701K	446K	-646K	112K
Change in Receivables	-190.94K	167.28K	-893.21K	790.99K	89.48K	-170.5K	50.15K	140K	-290K	141K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	3K	0	0	-156K
Cash from Investing+	-11.04K	-2.03M	1.94M	-6.27M	-2.08M	-1.85M	-139K	-836K	-637K	-12K
Capital Expenditures	-8.73K	-5.19K	-1.3M	-6.35M	-2.15M	-1.91M	-139K	-836K	-637K	-12K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	1.82%
Acquisitions	0	0	0	0	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2.31K	-2.02M	3.35M	74.07K	66.6K	61.29K	0	0	0	0
Cash from Financing+	8.66M	0	17.77M	22.55M	24.68M	4.27M	21.43M	6.78M	1.09M	3.44M
Debt Issued (Net)	0	0	0	22.55M	4.27M	-385.8K	-392.62K	0	0	0
Equity Issued (Net)	0	0	0	0	0	1000K	1000K	1000K	139K	1000K
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0
Other Financing	8.66M	0	17.77M	0	20.4M	304.35K	392.62K	26.51K	947K	1.44M
Net Change in Cash	6.12M	-4.51M	16.44M	-222.68K	693.11K	-18.05M	14.44M	-3.3M	-9.21M	-2.92M
Free Cash Flow+	-2.64M	-2.51M	-4.18M	-21.64M	-24.47M	-24.48M	-7.57M	-8.1M	-10.02M	-6.35M
FCF Margin %	-	-	-	-	-	-	-	-	-	-964.59%
FCF Growth %	-35.5%	5.03%	-66.64%	-417.23%	-13.06%	-0.05%	69.09%	-7.09%	-23.68%	36.65%
FCF per Share	-100.21	-74.34	-83.25	-331.11	-299.59	-220.88	-53.60	-42.97	-25.65	-7.87
FCF Conversion (FCF/Net Income)	1.01x	1.05x	0.29x	0.65x	0.71x	16.28x	0.90x	1.25x	1.44x	-1.32x
Interest Paid	5.9K	7.01K	20.98K	12.3K	37.93K	14K	0	916K	833K	143K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-40.68%	-31.25%	-87.05%	-600.05%	-	-	-835.64%	-	-	177.37%
Return on Invested Capital (ROIC)	-240.49%	-178.78%	-	-	-	29.46%	-62.1%	-89.45%	-86.51%	-61.06%
Gross Margin	-	-	-	-	-	-	-	-	-	-88.15%
Net Margin	-	-	-	-	-	-	-	-	-	728.88%
Debt / Equity	-	-	-	-	-	-	29.77x	-	-	0.21x
Interest Coverage	-371746.74x	-30890.00x	-332.39x	-5.45x	-5.30x	6.54x	-3.23x	-2.19x	-1216.44x	-6.00x
FCF Conversion	1.01x	1.05x	0.29x	0.65x	0.71x	16.28x	0.90x	1.25x	1.44x	-1.32x

US Stock Screener

...

Scinai Immunotherapeutics Ltd. (SCNI) 10-Year Financial Performance & Capital Metrics

SCNI •

HealthcareBiotechnologyVaccines and Infectious Disease

Revenue $658K
EBITDA -$7M +24.0%
Net Income $5M +173.8%
EPS (Diluted) 6.00 +135.7%
Gross Margin -88.15%
EBITDA Margin -1062.16%
Operating Margin -1312.77%
Net Margin 728.88%
ROE 177.37%
ROIC -61.06% +29.4%
Debt/Equity 0.21
Interest Coverage -6.00 +99.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 177.4%
✓Healthy 5Y average net margin of 728.9%
✓Trading at only 0.1x book value

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM303.87%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM224.43%

EPS CAGR

10Y-

5Y-

3Y-

TTM-100%

ROCE

10Y Avg-51.96%

5Y Avg-42.76%

3Y Avg-50.65%

Latest-63.2%

Peer Comparison

Vaccines and Infectious Disease

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
NVAXNovavax, Inc.	1.67B	10.14	3.93	64.69%	39.19%
SCNIScinai Immunotherapeutics Ltd.	3.03B	0.89	0.15		401.83%	58.65%		0.21
TNXPTonix Pharmaceuticals Holding Corp.	142.05M	13.97	-0.08	29.94%	-9.63%	-42.93%		0.04
INOInovio Pharmaceuticals, Inc.	65.34M	1.81	-0.46	-73.83%	-592.82%	-115.42%		0.17
IVVDInvivyd, Inc.	362.35M	1.69	-1.18		-119.63%	-64.32%		0.02
SPROSpero Therapeutics, Inc.	122.2M	2.17	-1.71	-53.77%	-122.56%	-165.46%		0.09
AVIRAtea Pharmaceuticals, Inc.	365.63M	4.68	-2.34			-46.56%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	658K
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	123.55K	72.32K	461.69K	708.92K	747.65K	559.8K	512.67K	1.24M
COGS % of Revenue	-	-	-	-	-	-	-	-	-	188.15%
Gross Profit+	0	0	0	0	0	-708.92K	-747.65K	-559.8K	-512.67K	-580K
Gross Margin %	-	-	-	-	-	-	-	-	-	-88.15%
Gross Profit Growth %	-	-	-	-	-	-	-5.46%	25.13%	8.42%	-13.13%
Operating Expenses+	2.9M	3.09M	6.8M	20.61M	22.69M	-2.28M	10.86M	11.06M	9.71M	8.06M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	1224.62%
Selling, General & Admin	871.81K	1.07M	1.4M	1.38M	2.81M	5.02M	7.63M	5.3M	4.5M	2.53M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	383.89%
Research & Development	1.91M	2.44M	5.58M	19.27M	19.88M	16.01M	3.25M	5.76M	5.21M	5.53M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	840.73%
Other Operating Expenses	-726K	-416K	-186K	-38.24K	0	-23.31M	-12K	0	-9K	0
Operating Income+	-2.9M	-3.09M	-6.8M	-20.61M	-22.69M	2.28M	-10.87M	-11.06M	-9.71M	-8.64M
Operating Margin %	-	-	-	-	-	-	-	-	-	-1312.77%
Operating Income Growth %	-38.83%	-6.48%	-120.07%	-203.15%	-10.1%	110.06%	-576.51%	-1.72%	12.25%	11%
EBITDA+	-2.74M	-2.93M	-6.67M	-20.54M	-22.23M	2.75M	-10.4M	-10.5M	-9.19M	-6.99M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-1062.16%
EBITDA Growth %	-42.98%	-6.84%	-128.05%	-207.68%	-8.24%	112.37%	-478.21%	-0.92%	12.45%	23.97%
D&A (Non-Cash Add-back)	161.62K	162.32K	123.55K	72.32K	461.69K	468.56K	471K	562K	514K	1.65M
EBIT	-2.9M	-3.09M	-6.8M	-20.61M	-22.69M	2.28M	-10.86M	-11.06M	-9.71M	-8.64M
Net Interest Income+	2.82K	14.28K	5.17K	-2.43M	-4.27M	-348K	-3.36M	3.05M	115K	-1.34M
Interest Income	2.83K	14.38K	5.04K	1.35M	8.3K	582	929	8.1M	122.68K	100.47K
Interest Expense	8	100	20.45K	3.78M	4.28M	348.93K	3.36M	5.05M	7.98K	1.44M
Other Income/Expense	283.33K	704.94K	-3.13M	-2.85M	-8.93M	-3.67M	2.67M	5.26M	3.21M	13.43M
Pretax Income+	-2.62M	-2.38M	-9.93M	-23.46M	-31.62M	-1.39M	-8.21M	-5.8M	-6.5M	4.8M
Pretax Margin %	-	-	-	-	-	-	-	-	-	728.88%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Net Income+	-2.62M	-2.38M	-9.93M	-23.46M	-31.62M	-1.39M	-8.21M	-5.8M	-6.5M	4.8M
Net Margin %	-	-	-	-	-	-	-	-	-	728.88%
Net Income Growth %	-31.33%	8.9%	-316.53%	-136.24%	-34.79%	95.62%	-492.06%	29.37%	-12.15%	173.78%
Net Income (Continuing)	-2.62M	-2.38M	-9.93M	-23.46M	-31.62M	-1.39M	-8.21M	-5.8M	-6.5M	4.8M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-396880.00	-282320.00	-790280.00	-999999.00	-999999.00	-12.40	-80.00	-30.80	-16.80	6.00
EPS Growth %	32.42%	28.87%	-179.92%	-81.68%	-7.87%	100%	-545.16%	61.5%	45.45%	135.71%
EPS (Basic)	-396880.00	-282320.00	-790280.00	-999999.00	-999999.00	-12.40	-87.60	-30.80	-16.80	6.00
Diluted Shares Outstanding	26.38K	33.77K	50.26K	65.36K	81.66K	110.81K	141.14K	188.52K	390.66K	806.37K
Basic Shares Outstanding	26.38K	33.77K	50.26K	65.35K	81.66K	110.81K	102.57K	188.52K	390.66K	806.37K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	9.48M	6.78M	21.64M	20.55M	21.17M	3.31M	17.84M	14.37M	5.45M	2.39M
Cash & Short-Term Investments	9.11M	6.57M	20.51M	20.29M	20.98M	2.93M	17.37M	14.07M	4.87M	1.96M
Cash Only	8.59M	4.08M	20.51M	20.29M	20.98M	2.93M	17.37M	14.07M	4.87M	1.96M
Short-Term Investments	517.39K	2.5M	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	71.22K	325.15K	0	330K	217K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	120.37
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	360.07K	198.3K	911.89K	102.42K	101.06K	33	-84.15K	250K	176K	131K
Total Non-Current Assets+	1.12M	1.03M	1.84M	7.75M	12.34M	14.4M	14.19M	12.7M	12.03M	11.06M
Property, Plant & Equipment	524.57K	374.53K	1.58M	7.55M	12.19M	14.25M	14.19M	12.7M	12.03M	11.06M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	0.06x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	525.6K	532.08K	0	0	0	147.31K	0	0	0	0
Other Non-Current Assets	73.66K	124.07K	252.9K	197.88K	150.16K	-150	0	0	0	0
Total Assets+	10.6M	7.82M	23.48M	28.3M	33.52M	17.71M	32.04M	27.07M	17.47M	13.45M
Asset Turnover	-	-	-	-	-	-	-	-	-	0.05x
Asset Growth %	123.73%	-26.28%	200.42%	20.54%	18.43%	-47.17%	80.93%	-15.51%	-35.45%	-23.03%
Total Current Liabilities+	436.03K	356.88K	1.98M	5.83M	5.49M	19.97M	2.44M	2.34M	1.78M	1.81M
Accounts Payable	238.93K	178.05K	1.79M	5.54M	4.94M	581.19K	999K	716K	535K	376K
Days Payables Outstanding	-	-	5.28K	27.97K	3.91K	299.24	487.71	466.84	380.89	110.86
Short-Term Debt	0	0	0	0	0	18.8M	248.36K	0	396K	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	225K
Other Current Liabilities	0	-190	0	0	0	0	-248.36K	0	-396K	0
Current Ratio	21.74x	19.01x	10.94x	3.53x	3.86x	0.17x	7.30x	6.15x	3.06x	1.32x
Quick Ratio	21.74x	19.01x	10.94x	3.53x	3.86x	0.17x	7.30x	6.15x	3.06x	1.32x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.56M	809.54K	5.33M	30.82M	46.87M	2.28M	28.61M	26.49M	20.26M	1.67M
Long-Term Debt	0	0	0	25.23M	35.84M	0	27.16M	20.08M	19.37M	260K
Capital Lease Obligations	0	0	0	0	1.97M	1.89M	1.45M	1.08M	797K	1.4M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.56M	809.54K	5.33M	5.59M	9.06M	382.69K	30.52K	5.33M	96K	3K
Total Liabilities	1.99M	1.17M	7.31M	36.65M	52.36M	22.25M	31.05M	28.83M	22.04M	3.47M
Total Debt+	0	0	0	25.23M	38.02M	20.9M	29.23M	21.54M	20.56M	2.09M
Net Debt	-8.59M	-4.08M	-20.51M	4.94M	17.03M	17.97M	11.86M	7.47M	15.69M	122K
Debt / Equity	-	-	-	-	-	-	29.77x	-	-	0.21x
Debt / EBITDA	-	-	-	-	-	7.60x	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	6.53x	-	-	-	-
Interest Coverage	-371746.74x	-30890.00x	-332.39x	-5.45x	-5.30x	6.54x	-3.23x	-2.19x	-1216.44x	-6.00x
Total Equity+	8.61M	6.65M	16.17M	-8.35M	-18.84M	-4.54M	982K	-1.76M	-4.57M	9.98M
Equity Growth %	102.23%	-22.77%	143.15%	-151.63%	-125.68%	75.89%	121.62%	-279.23%	-159.6%	318.36%
Book Value per Share	326.33	196.86	321.66	-127.72	-230.68	-40.98	6.96	-9.34	-11.70	12.37
Total Shareholders' Equity	8.61M	6.65M	16.17M	-8.35M	-18.84M	-4.54M	982K	-1.76M	-4.57M	9.98M
Common Stock	0	0	0	0	0	0	0	0	0	0
Retained Earnings	-20.45M	-23.07M	-35.47M	-56.46M	-92.76M	-101.05M	-110.04M	-115.83M	-122.33M	-117.54M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	653.92K	374.01K	0	0	0	0	-2.06M	-2.01M	-1.74M	-1.74M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.63M	-2.51M	-2.89M	-15.29M	-22.31M	-22.57M	-7.43M	-7.26M	-9.38M	-6.33M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-962.77%
Operating CF Growth %	-35.58%	4.91%	-15.28%	-429.52%	-45.9%	-1.14%	67.1%	2.17%	-29.14%	32.48%
Net Income	-2.62M	-2.38M	-9.93M	-23.46M	-31.62M	-1.3M	-8.21M	-5.8M	-6.5M	4.8M
Depreciation & Amortization	161.17K	162.32K	126.45K	69.53K	476.36K	757.91K	471K	562K	514K	1.65M
Stock-Based Compensation	191.2K	327.29K	149.16K	69.53K	1.07M	2.95M	2.76M	1.6M	1.14M	682K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-176.31K	-756.95K	7.67M	7.12M	7.64M	-25.17M	-3.15M	-4.08M	-3.89M	-13.57M
Working Capital Changes	-193.51K	145.61K	-901.54K	902.23K	126.26K	196.01K	701K	446K	-646K	112K
Change in Receivables	-190.94K	167.28K	-893.21K	790.99K	89.48K	-170.5K	50.15K	140K	-290K	141K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	3K	0	0	-156K
Cash from Investing+	-11.04K	-2.03M	1.94M	-6.27M	-2.08M	-1.85M	-139K	-836K	-637K	-12K
Capital Expenditures	-8.73K	-5.19K	-1.3M	-6.35M	-2.15M	-1.91M	-139K	-836K	-637K	-12K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	1.82%
Acquisitions	0	0	0	0	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2.31K	-2.02M	3.35M	74.07K	66.6K	61.29K	0	0	0	0
Cash from Financing+	8.66M	0	17.77M	22.55M	24.68M	4.27M	21.43M	6.78M	1.09M	3.44M
Debt Issued (Net)	0	0	0	22.55M	4.27M	-385.8K	-392.62K	0	0	0
Equity Issued (Net)	0	0	0	0	0	1000K	1000K	1000K	139K	1000K
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	0	0	0	0	0
Other Financing	8.66M	0	17.77M	0	20.4M	304.35K	392.62K	26.51K	947K	1.44M
Net Change in Cash	6.12M	-4.51M	16.44M	-222.68K	693.11K	-18.05M	14.44M	-3.3M	-9.21M	-2.92M
Free Cash Flow+	-2.64M	-2.51M	-4.18M	-21.64M	-24.47M	-24.48M	-7.57M	-8.1M	-10.02M	-6.35M
FCF Margin %	-	-	-	-	-	-	-	-	-	-964.59%
FCF Growth %	-35.5%	5.03%	-66.64%	-417.23%	-13.06%	-0.05%	69.09%	-7.09%	-23.68%	36.65%
FCF per Share	-100.21	-74.34	-83.25	-331.11	-299.59	-220.88	-53.60	-42.97	-25.65	-7.87
FCF Conversion (FCF/Net Income)	1.01x	1.05x	0.29x	0.65x	0.71x	16.28x	0.90x	1.25x	1.44x	-1.32x
Interest Paid	5.9K	7.01K	20.98K	12.3K	37.93K	14K	0	916K	833K	143K
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-40.68%	-31.25%	-87.05%	-600.05%	-	-	-835.64%	-	-	177.37%
Return on Invested Capital (ROIC)	-240.49%	-178.78%	-	-	-	29.46%	-62.1%	-89.45%	-86.51%	-61.06%
Gross Margin	-	-	-	-	-	-	-	-	-	-88.15%
Net Margin	-	-	-	-	-	-	-	-	-	728.88%
Debt / Equity	-	-	-	-	-	-	29.77x	-	-	0.21x
Interest Coverage	-371746.74x	-30890.00x	-332.39x	-5.45x	-5.30x	6.54x	-3.23x	-2.19x	-1216.44x	-6.00x
FCF Conversion	1.01x	1.05x	0.29x	0.65x	0.71x	16.28x	0.90x	1.25x	1.44x	-1.32x

Scinai Immunotherapeutics Ltd. (SCNI) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare SCNI vs Peers

vs BNTX

vs MRNA

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Scinai Immunotherapeutics Ltd. (SCNI) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare SCNI vs Peers

vs BNTX

vs MRNA

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios